ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2)

An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)

Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

Study Overview

• Status: Recruiting
• Conditions: Liver Neoplasms; Hepatocellular Carcinoma (HCC); Liver Cancer; Hepatoblastoma; Metastatic Liver Cancer; HEMNOS
• Intervention / Treatment: Drug: ET140203 T Cells

Detailed Description

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of intravenous (IV) administration of ET140203 T cells and determine the recommended Phase II dose (RP2D) of ET140203 T-cell therapy in pediatric subjects (age ≥ 1 year and ≤ 21 years) who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

A traditional dose escalation model (3+3 design) will be used to determine the RP2D, and once determined, the expansion phase will commence. A statistically relevant number of subjects will be treated at the RP2D in the expansion phase to adequately assess the therapeutic benefits and risks of ET140203 T-cell therapy. Tumor response assessments will be performed prior to 1st infusion (baseline) and at Months 1, 3, 6, 9, 12, 18, and 24. At each tumor response assessment visit, radiographic imaging will be performed and used for response evaluation. Serum AFP levels will also be measured at each tumor response assessment visit.

The active assessment period of the study will continue for 2 years. Subjects will be followed for assessment of treatment safety and overall survival during long-term follow-up (LTFU; Year 2-15).

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Pei Wang, PhD; Phone Number: 510-654-7045; Email: Pei.Wang@eurekainc.com
• Study Contact Backup: Name: Teresa Klask, MBA; Phone Number: 412 510-722-8719; Email: Teresa.Klask@eurekainc.com

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90027
      • Recruiting
      • Children's Hospital Los Angeles
      • Contact: Silpa Sharma, MPH, CCRC; Phone Number: 323-361-6475; Email: sisharma@chla.usc.edu
      • Principal Investigator: Rachana Shah, MD, MS
    • Orange, California, United States, 92868
      • Recruiting
      • Children's Hospital Orange County
      • Contact: Dorian Chan; Phone Number: 714-509-7868; Email: dchan@choc.org
      • Principal Investigator: Rishikesh Chavan, MD
    • San Francisco, California, United States, 94158
      • Recruiting
      • UCSF Benioff Children's Hospitals
      • Principal Investigator: Arun Rangaswami, MD
      • Contact: Brian Luong, CCRP; Email: Brian.Luong@ucsf.edu
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Recruiting
      • Dana-Farber/Boston Children's Cancer and Blood Disorders Center
      • Principal Investigator: Allison O'Neill, MD
      • Contact: Jill MacDonald; Phone Number: 617-632-4930; Email: Jill_Macdonald@DFCI.Harvard.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 17 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Histologically confirmed HB, HCN-NOS, or HCC with serum AFP >100ng/mL at the time of screening and following the most recent line of therapy.
2. Disease recurrence after remission following initial standard-of care (SOC) treatment (i.e., relapse) or failure of response to SOC treatment (i.e., refractory).
3. Age ≥ 1 year and ≤ 21 years.
4. Molecular Human Leukocyte Antigen (HLA) class I allele typing that confirms subject carries at least one HLA-A2 allele.
5. Life expectancy of > 4 months per the Investigator's opinion.
6. Lansky or Karnofsky Performance Scale ≥ 70.
7. For enrollment to the dose-finding cohort, subjects must have at least one (1) lesion ≥ 5 mm in diameter or two (2) or more lesions ≥ 3 mm in diameter. For the dose-expansion cohort, subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
8. Child-Pugh score of A6 or better.
9. Adequate organ function.

Exclusion Criteria:

1. Recurrent HB who are candidates for complete surgical resection (e.g., isolated pulmonary relapse amendable to pulmonary metastasectomy).
2. Pre-existing illness including heart failure, uncontrolled pulmonary disease not cancer-related, or psychiatric illness/social situation that would limit compliance with study requirements.
3. Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled.
4. Any known active malignancy (other than HB, HCN-NOS, or HCC).
5. Pregnant or lactating women.
6. Received the following within one (1) week of leukapheresis or within two (2) weeks of conditioning chemotherapy: cytotoxic chemotherapy, radiation, other anti-cancer therapies (including immunotherapeutic agents), or immunosuppressive therapy. Systemic corticosteroids at doses greater than 5 mg/day of prednisone or equivalent doses of other corticosteroids within two (2) weeks prior to leukapheresis or conditioning chemotherapy or receipt of a T-cell engager (TCE) within two (2) months prior to leukapheresis or at any time as bridging therapy between leukapheresis and conditioning chemotherapy is exclusionary. (Note: Topical and inhaled corticosteroids in standard doses and physiological replacement doses of corticosteroids for adrenal insufficiency are allowed).
7. Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study.
8. Contraindication for receipt of conditioning chemotherapeutic agents including Fludarabine and Cyclophosphamide.
9. Active autoimmune disease requiring systemic immunosuppressive therapy.
10. Compromised circulation in the main portal vein, hepatic vein, or vena cava due to partial or complete obstruction which, in the opinion of the Investigator, would make the subject unsuitable for the study.
11. History of organ transplant.
12. HB, HCN-NOS, or HCC involving greater than 50% of the liver (volumetric).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ET140203 T Cells; ET140203 Autologous T Cells	Drug: ET140203 T Cells; Biological/Vaccine: ET140203 autologous T-cell product Autologous T cells transduced with lentivirus encoding an ET140203 expression construct

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence rates of adverse events (AEs) after infusion of ET140203 T cells	Safety of ET140203 T cells as assessed by the number of adverse events (AEs) after infusion	28 days
Severity rates of adverse events (AEs) after infusion of ET140203 T cells	Safety of ET140203 T cells as assessed by the severity of adverse events (AEs) after infusion.	28 days
Incidence rates of dose limiting toxicities (DLTs) after infusion of ET140203 T cells	Tolerability of ET140203 T cells after infusions assessed by committee review of dose limiting toxicities (DLTs)	28 days
The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLT	The RP2D will be determined by the study Dose Escalation Committee (DEC) and primarily based on DLTs.	Up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assess the efficacy of ET140203 T cells in pediatric subjects with relapsed/refractory HB, HCN-NOS, or HCC	Response rate will be assessed by radiographic scans and assessed according to RECIST criteria.	Up to 2 years
Determine the pharmacokinetics of ET140203 T cells after infusion.	Assess the expansion and persistence of ET140203 T cells circulating in blood over time.	Up to 2 years

Collaborators and Investigators

• Sponsor: Eureka Therapeutics Inc.
• Investigators: Study Director: Pei Wang, PhD, Eureka Therapeutics Inc.

Study record dates

Study Major Dates

• Study Start (Actual): July 19, 2022
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): January 31, 2028

Study Registration Dates

• First Submitted: November 4, 2020
• First Submitted That Met QC Criteria: November 12, 2020
• First Posted (Actual): November 18, 2020

Study Record Updates

• Last Update Posted (Actual): July 6, 2026
• Last Update Submitted That Met QC Criteria: July 1, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Pediatric; Liver Cancer; Hepatocellular Carcinoma (HCC); T-cell therapy; Metastatic Liver Cancer; Relapsed/Refractory Hepatoblastoma (HB); Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS); Liver neoplasms; HEMNOS
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Digestive System Neoplasms; Digestive System Diseases; Liver Diseases; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma; Neoplasms, Complex and Mixed; Carcinoma, Hepatocellular; Liver Neoplasms; Hepatoblastoma
• Other Study ID Numbers: ETUS20AFPAR123

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No